Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > What is the success rate of clinical drug development?

<< Previous

Bullboard Posts

Next >>

Comment by Chianchinon Aug 10, 2023 3:26am

160 Views

Post# 35581062

RE:RE:RE:What is the success rate of clinical drug development?

Mr micky mugsy, you have lost your shirt and all on ATE, nothing left to invest other than writing on this board with bS. Two Years ago ATE did a reverse consolidation when it trades at $.50. 10 share became one share. So ATE traded arrounf $4.50. now it trades back at $50 again. By now you have lost over 90% of your money and you claim to know about investing. LOL

<< Previous

Bullboard Posts

Next >>

StockTalk | Cannabis Report: New CEO, new dispensaries, new strains